Clinical Trials
27 trialsA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
M.D. Anderson Cancer Center
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
REPOTHYROID-II
Radboud University Medical Center
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
SEACRAFT-1
Erasca, Inc.
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NEO-COMBATXL
UNC Lineberger Comprehensive Cancer Center
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery
National Taiwan University Hospital
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Ikena Oncology
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins